Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hematologic Neoplasms 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Lymphoma, Non-Hodgkin 12Myeloproliferative Disorders 11Lymphoma 11Leukemia, Myelomonocytic, Chronic 11Graft vs Host Disease 10Primary Myelofibrosis 9Leukemia 9Hodgkin Disease 9Leukemia, Lymphocytic, Chronic, B-Cell 7Anemia, Refractory, with Excess of Blasts 7Multiple Myeloma 6Leukemia, Biphenotypic, Acute 6Burkitt Lymphoma 5Polycythemia Vera 4Lymphoma, Follicular 4Leukemia, Myeloid 4Leukemia, Lymphoid 4Anemia, Aplastic 4Thrombocythemia, Essential 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Neoplasms, Plasma Cell 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoproliferative Disorders 3

Interventions

pembrolizumab 18Nivolumab 13avelumab 10Ipilimumab 7Specimen Handling 6cemiplimab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Radiotherapy 3Cyclophosphamide 3prednylidene 2poly ICLC 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Radiosurgery 2Prednisone 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2CTLA-4 Antigen 2Bevacizumab 2tocilizumab 1talimogene laherparepvec 1sargramostim 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Tacrolimus × 1 year × Clear all
NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡